Arcadia Biosciences Q2 FY26 net loss widens 41% to $6.27 million; revenue slips 1% to $1.44 million

Reuters2026/08/13 20:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arcadia Biosciences posted Q2 net loss attributable to common stockholders of USD 6.27 million, worsening 41% year over year.
Revenue slipped 1% to USD 1.44 million, while operating loss narrowed to USD 496,000 from USD 501,000.
First-half net loss attributable to common stockholders widened to USD 10.65 million from USD 1.86 million.
Six-month revenue fell 4% to USD 2.54 million on low inventory balances and longer-than-expected shipping times.
Ended Q2 with USD 4.2 million cash after a USD 4 million private placement; July Zola sales topped USD 740,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcadia Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809585) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arcadia Biosciences Q2 FY26 net loss widens 41% to $6.27 million; revenue slips 1% to $1.44 million

You may also like

Crypto prices